Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907431347> ?p ?o ?g. }
- W2907431347 endingPage "206" @default.
- W2907431347 startingPage "194" @default.
- W2907431347 abstract "BackgroundBRAF inhibitor (BRAF-I) therapy for melanoma patients harboring the V600E mutation is initially highly effective, but almost all patients relapse within a few months. Understanding the molecular mechanisms behind BRAF-I responsiveness and acquired resistance is therefore an important issue. Here we assessed the role of urokinase type plasminogen activator receptor (uPAR) as a potentially valuable biomarker in the acquisition of BRAF-I resistance in V600E mutant melanoma cells.MethodsWe examined uPAR and EGFR levels by real time PCR and western blot analysis. uPAR loss of function was realized by knocking down uPAR by RNAi or using M25, a peptide that uncouples uPAR-integrin interaction. We investigated uPAR-β1integrin-EGFR association by co-immunoprecipitation and confocal immuno-fluorescence analysis. Acquired resistance to BRAF-I was generated by chronic exposure of cells to vemurafenib.FindingsWe proved that uPAR knockdown in combination with vemurafenib inhibits melanoma cell proliferation to greater extent than either treatment alone causing a decrease in AKT and ERK1/2 phosphorylation. Conversely, we demonstrated that uPAR enforced over-expression results in reduced sensitivity to BRAF inhibition. Moreover, by targeting uPAR and EGFR interaction with an integrin antagonist peptide we restored vemurafenib responsiveness in melanoma resistant cells. Furthermore, we found significant detectable uPAR and EGFR levels in tumor biopsies of 4 relapsed patients.InterpretationWe disclosed an unpredicted mechanism of reduced sensitiveness to BRAF inhibition, driven by elevated levels of uPAR and identified a potential therapeutic strategy to overcome acquired resistance.FundsAssociazione Italiana Ricerca sul Cancro (AIRC); Ente Cassa di Risparmio di Firenze." @default.
- W2907431347 created "2019-01-11" @default.
- W2907431347 creator A5008440351 @default.
- W2907431347 creator A5010943353 @default.
- W2907431347 creator A5017421300 @default.
- W2907431347 creator A5017879151 @default.
- W2907431347 creator A5043343391 @default.
- W2907431347 creator A5046921190 @default.
- W2907431347 creator A5048102453 @default.
- W2907431347 creator A5054767907 @default.
- W2907431347 creator A5066829766 @default.
- W2907431347 creator A5066841020 @default.
- W2907431347 creator A5076836970 @default.
- W2907431347 creator A5083162950 @default.
- W2907431347 date "2019-01-01" @default.
- W2907431347 modified "2023-09-23" @default.
- W2907431347 title "EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells" @default.
- W2907431347 cites W1520012482 @default.
- W2907431347 cites W1527111349 @default.
- W2907431347 cites W1819015028 @default.
- W2907431347 cites W1950572133 @default.
- W2907431347 cites W1966504629 @default.
- W2907431347 cites W1971947883 @default.
- W2907431347 cites W1972671597 @default.
- W2907431347 cites W1977889509 @default.
- W2907431347 cites W1985928174 @default.
- W2907431347 cites W1987393705 @default.
- W2907431347 cites W1990511191 @default.
- W2907431347 cites W1996030902 @default.
- W2907431347 cites W1997919830 @default.
- W2907431347 cites W2004295816 @default.
- W2907431347 cites W2007964976 @default.
- W2907431347 cites W2014040082 @default.
- W2907431347 cites W2014881369 @default.
- W2907431347 cites W2015314629 @default.
- W2907431347 cites W2017187984 @default.
- W2907431347 cites W2018930320 @default.
- W2907431347 cites W2019607817 @default.
- W2907431347 cites W2020671978 @default.
- W2907431347 cites W2024126123 @default.
- W2907431347 cites W2025739511 @default.
- W2907431347 cites W2026196315 @default.
- W2907431347 cites W2030459426 @default.
- W2907431347 cites W2040526629 @default.
- W2907431347 cites W2042555223 @default.
- W2907431347 cites W2043058822 @default.
- W2907431347 cites W2044297092 @default.
- W2907431347 cites W2048711939 @default.
- W2907431347 cites W2080258889 @default.
- W2907431347 cites W2085351616 @default.
- W2907431347 cites W2092565468 @default.
- W2907431347 cites W2095032529 @default.
- W2907431347 cites W2097941009 @default.
- W2907431347 cites W2101176998 @default.
- W2907431347 cites W2105437003 @default.
- W2907431347 cites W2111381709 @default.
- W2907431347 cites W2112981251 @default.
- W2907431347 cites W2114903025 @default.
- W2907431347 cites W2115022202 @default.
- W2907431347 cites W2121799544 @default.
- W2907431347 cites W2125524879 @default.
- W2907431347 cites W2132923173 @default.
- W2907431347 cites W2133540186 @default.
- W2907431347 cites W2141606844 @default.
- W2907431347 cites W2144096834 @default.
- W2907431347 cites W2146557091 @default.
- W2907431347 cites W2147241956 @default.
- W2907431347 cites W2152061559 @default.
- W2907431347 cites W2155420645 @default.
- W2907431347 cites W2155461614 @default.
- W2907431347 cites W2163188200 @default.
- W2907431347 cites W2164921896 @default.
- W2907431347 cites W2167871997 @default.
- W2907431347 cites W2168143310 @default.
- W2907431347 cites W2171367970 @default.
- W2907431347 cites W2397947982 @default.
- W2907431347 cites W2599036871 @default.
- W2907431347 cites W2620681921 @default.
- W2907431347 cites W2747033326 @default.
- W2907431347 cites W2747234998 @default.
- W2907431347 cites W2768840317 @default.
- W2907431347 cites W2776664321 @default.
- W2907431347 cites W2795239550 @default.
- W2907431347 cites W2795377613 @default.
- W2907431347 doi "https://doi.org/10.1016/j.ebiom.2018.12.024" @default.
- W2907431347 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6355443" @default.
- W2907431347 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30611716" @default.
- W2907431347 hasPublicationYear "2019" @default.
- W2907431347 type Work @default.
- W2907431347 sameAs 2907431347 @default.
- W2907431347 citedByCount "29" @default.
- W2907431347 countsByYear W29074313472019 @default.
- W2907431347 countsByYear W29074313472020 @default.
- W2907431347 countsByYear W29074313472021 @default.
- W2907431347 countsByYear W29074313472022 @default.
- W2907431347 crossrefType "journal-article" @default.
- W2907431347 hasAuthorship W2907431347A5008440351 @default.
- W2907431347 hasAuthorship W2907431347A5010943353 @default.